WallStreetZenWallStreetZen

NASDAQ: LSTA
Lisata Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Should I buy or sell LSTA stock?

Based on 1 analyst offering ratings for Lisata Therapeutics Inc.

Hold
Strong Buy
0 analysts 0%
Buy
0 analysts 0%
Hold
1 analysts 100%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their LSTA stock forecasts and price targets.

LSTA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-05-15

1 of 1

Forecast return on equity

Is LSTA forecast to generate an efficient return?

Company
N/A
Industry
15.42%
Market
167.66%

Forecast return on assets

Is LSTA forecast to generate an efficient return on assets?

Company
N/A
Industry
23.17%

LSTA earnings per share forecast

What is LSTA's earnings per share in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$0.98
Avg 2 year Forecast
-$0.67
Avg 3 year Forecast
-$1.00

LSTA revenue forecast

What is LSTA's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.0-100%
Avg 2 year Forecast
$5.1M+5,000%
Avg 3 year Forecast
$7.3M+7,244%
LSTA's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

LSTA revenue growth forecast

How is LSTA forecast to perform vs Biotechnology companies and vs the US market?

Company
329.36%
Industry
31.75%
Market
13.42%
LSTA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
LSTA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

LSTA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
LSTA$1.69N/AN/AHold
NCEL$3.19$23.00+621.00%Strong Buy
HIND$2.21N/AN/A
GRML$4.88N/AN/A
AEON$0.31$1.20+282.17%Buy
View Top Biotech Stocks

Lisata Therapeutics Stock Forecast FAQ

Is Lisata Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: LSTA) stock is to Hold LSTA stock.

Out of 1 analyst, 0 (0%) are recommending LSTA as a Strong Buy, 0 (0%) are recommending LSTA as a Buy, 1 (100%) are recommending LSTA as a Hold, 0 (0%) are recommending LSTA as a Sell, and 0 (0%) are recommending LSTA as a Strong Sell.

If you're new to stock investing, here's how to buy Lisata Therapeutics stock.

What is LSTA's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: LSTA) Lisata Therapeutics's current Earnings Per Share (EPS) is -$1.64. On average, analysts forecast that LSTA's EPS will be -$0.98 for 2026, with the lowest EPS forecast at -$0.94, and the highest EPS forecast at -$1.01. On average, analysts forecast that LSTA's EPS will be -$0.67 for 2027, with the lowest EPS forecast at -$0.65, and the highest EPS forecast at -$0.69. In 2028, LSTA's EPS is forecast to hit -$1.00 (min: -$0.96, max: -$1.03).

What is LSTA's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: LSTA) forecast ROE is N/A, which is considered weak.

What is LSTA's earnings growth forecast for 2026-2028?

(NASDAQ: LSTA) Lisata Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.06%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 30.99%.

Lisata Therapeutics's earnings in 2026 is -$14,621,000.On average, 3 Wall Street analysts forecast LSTA's earnings for 2026 to be -$8,823,510, with the lowest LSTA earnings forecast at -$8,477,490, and the highest LSTA earnings forecast at -$9,083,024. On average, 3 Wall Street analysts forecast LSTA's earnings for 2027 to be -$6,066,163, with the lowest LSTA earnings forecast at -$5,828,274, and the highest LSTA earnings forecast at -$6,244,579.

In 2028, LSTA is forecast to generate -$9,007,333 in earnings, with the lowest earnings forecast at -$8,654,104 and the highest earnings forecast at -$9,272,254.

What is LSTA's revenue growth forecast for 2026-2028?

(NASDAQ: LSTA) Lisata Therapeutics's forecast annual revenue growth rate of 329.36% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.75%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.42%.

Lisata Therapeutics's revenue in 2026 is $100,000.On average, 3 Wall Street analysts forecast LSTA's revenue for 2026 to be $0, with the lowest LSTA revenue forecast at $0, and the highest LSTA revenue forecast at $0. On average, 4 Wall Street analysts forecast LSTA's revenue for 2027 to be $45,955,779, with the lowest LSTA revenue forecast at $0, and the highest LSTA revenue forecast at $94,614,839.

In 2028, LSTA is forecast to generate $66,176,321 in revenue, with the lowest revenue forecast at $63,581,171 and the highest revenue forecast at $68,122,684.

What is LSTA's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: LSTA) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 23.17%.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.